8-K: FOXO Technologies to Spin Off Epigenetics Subsidiary FOXO Labs

FOXO Technologies Inc. announced its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary, focusing on its epigenetics business to unlock shareholder value and simplify business models.

Summary

• FOXO Technologies Inc. (FOXO) announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary.
• FOXO Labs, Inc. is focused on the development of FOXO's epigenetics business, which includes pioneering epigenetic biomarkers for underwriting protocols and consumer engagement tools.
• FOXO Labs owns Patent No. 11,817,214, titled 'Machine Learning Model Trained to Determine a Biochemical State and/or Medical Condition Using DNA Epigenetic Data'.
• The epigenetics technology provides health, lifestyle, and longevity insights from a single saliva sample, eliminating the need for invasive blood and urine collection.
• FOXO Labs is developing an 'ultimate health, fitness, and longevity coach' utilizing patented epigenetic analysis and a new proprietary AI model for personalized coaching.
• The spin-off is intended to create the best opportunity to deliver the business strategy and create value for FOXO and its shareholders.
• The spin-off aims to facilitate a simplified business model for each entity, with FOXO shareholders directly owning FOXO Labs, Inc. and FOXO Technologies, Inc. retaining some ownership.
• FOXO Technologies Inc. also owns and operates Rennova Community Health, Inc. (a critical access hospital) and Myrtle Recovery Centers, Inc. (a behavioral health facility).

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the company is announcing a strategic spin-off aimed at unlocking shareholder value, simplifying business operations, and capitalizing on a promising, high-growth segment (epigenetics and AI in health) with a potential subscription-based revenue model. The language used by management is optimistic about future opportunities.

Positives

• The spin-off is expected to create value for FOXO and its shareholders by allowing direct ownership in FOXO Labs, Inc. for FOXO shareholders.
• The strategy facilitates a simplified business model for both FOXO Technologies and the spun-off FOXO Labs.
• FOXO Labs, Inc. is seen as an exciting opportunity to build a subscription-based revenue model for personal health and longevity.
• FOXO Labs possesses patented technology (Patent No. 11,817,214) and is developing cutting-edge AI models for personalized health coaching.
• The epigenetics technology offers non-invasive health insights from saliva, which is a significant advantage over traditional methods.

Risks

• Changes in the competitive and highly regulated industries in which FOXO operates.
• Variations in operating performance across competitors or changes in laws and regulations affecting FOXO's businesses.
• The ability to implement FOXO's business plans, forecasts, and other expectations.
• The ability to obtain financing.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.
• The enforceability of FOXO's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others.
• The risk of downturns and a changing regulatory landscape in the highly competitive markets or industries in which FOXO operates.

Future Outlook

The company intends to deliver the spin-off of FOXO Labs, Inc. as soon as practical, aiming to create a simplified business model for each entity and build a subscription-based revenue model for personal health and longevity through FOXO Labs.

Management Comments

• Mark White, Chief Executive Officer of FOXO Labs, Inc. stated: "We are creating the ultimate health, fitness, and longevity coach leveraging our cutting-edge patented epigenetic analysis and a new proprietary AI model to deliver a deeply personalized coaching experience."
• Mark White, Chief Executive Officer of FOXO Labs, Inc. stated: "We believe spinning this business off creates the best opportunity to deliver our business strategy and create value for FOXO and its shareholders."
• Seamus Lagan, Chief Executive Officer of FOXO Technologies, Inc. stated: "We believe FOXO Labs, Inc., is an exciting opportunity to build a subscription-based revenue model for personal health and longevity."
• Seamus Lagan, Chief Executive Officer of FOXO Technologies, Inc. stated: "We believe a spin off whereby FOXO shareholders benefit from directly owning FOXO Labs, Inc. and by FOXO Technologies, Inc., retaining some ownership in the spun off Company, is a strategy that facilitates a simplified business model for each entity."
• Seamus Lagan, Chief Executive Officer of FOXO Technologies, Inc. stated: "We look forward to delivering this spin off as soon as practical."

Industry Context

The announcement positions FOXO Technologies to capitalize on the growing trends in personalized health, preventative medicine, and the integration of artificial intelligence with biotechnology. The focus on epigenetics and non-invasive testing aligns with increasing consumer demand for accessible and data-driven health insights, potentially disrupting traditional healthcare and wellness markets. The move to a subscription-based model for health coaching also reflects a broader industry shift towards recurring revenue streams in digital health.

Stakeholder Impact

• Shareholders: Expected to benefit from direct ownership in FOXO Labs, Inc. and potential value creation from a simplified business model and a focused epigenetics entity.
• Customers: FOXO Labs aims to provide advanced epigenetic testing services, bioinformatics tools, and a personalized AI health coach, offering new and improved health and wellness solutions.
• Employees: Implied continuity for employees within FOXO Labs, Inc. as it becomes a separate entity, focusing on its specialized business.

Next Steps

• Proceed with the spin-off of FOXO Labs, Inc. as soon as practical.

Key Dates

Keywords

Epigenetics, Spin-off, Biotechnology, AI Health Coach, Personalized Health, Longevity, Saliva Testing, Biomarkers, Healthcare Technology, Subscription Model, Corporate Restructuring